<DOC>
	<DOCNO>NCT01544491</DOCNO>
	<brief_summary>The purpose study determine everolimus combine reduced exposure CNI ( TAC ) efficacious safe support corticosteroid elimination compare standard exposure CNI ( TAC ) + MMF + steroid regimen paediatric kidney transplantation . An additional purpose study assess effect combination EVR reduce exposure CNI ( TAC ) renal function . This study part requirement Paediatric Investigational Plan approve Paediatric Committee European Medicines Agency ( PDCO/EMA ) September 10 , 2010 , intend support indication everolimus prevention acute rejection paediatric recipient renal transplant .</brief_summary>
	<brief_title>Efficacy , Tolerability Safety Early Introduction Everolimus , Reduced Calcineurin Inhibitors Early Steroid Elimination Compared Standard CNI , Mycophenolate Mofetil Steroid Regimen Paediatric Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criterion baseline : 1 . Written informed consent/assent must obtain parent ( ) legal guardian assessment perform . 2 . Primary secondary paediatric kidney transplant recipient age great equal 1 year younger 18 year receive decease donor nonHLA identical living donor ( relate unrelated ) renal transplant . Inclusion criterion randomization : 1 . Patients TAC + MMF + steroid . 2 . Renal function eGFR &gt; 40 ml/min/1.73 m2 ( Schwartz formula abbreviate ) . Exclusion criterion baseline : 1 . Recipients kidneys donor know renal disease ( diabetes nephropathy , nephrosclerosis ) , time transplant . 2 . Recipients kidney cold ischemia time &gt; 24 hour . 3 . History hypersensitivity contraindication study drug drug similar chemical class , excipients . 4 . History malignancy organ system treat untreated , carry possible risk recurrence accord current guideline ( Appendix 10 protocol ) . Exclusion criterion randomization : 1 . Use investigational drug time randomization , within 30 day 5 halflives prior randomization , whichever longer . 2 . Patients ongoing recently ( within 2 week prior randomization ) treat episode acute rejection ( grade ) steroid resistant acute rejection time randomization . 3 . Patients experience acute cellular rejection ( Banff ≥1B ) antibody mediate acute rejection patient consider high risk antibody mediate acute rejection investigator assessment ( e.g . presence newly form DSA , histological suspicion ) time randomization ( DSA quantitative threshold define high risk fully establish , assessment risk make discussion laboratory expert investigator take account information available apply best judgment ) . 4 . Patients ongoing wound heal problem , clinically significant wound infection require continue therapy severe surgical complication opinion investigator . 5 . Patients treat drug strong inducer inhibitor cytochrome P450 3A4 ( CYP3A4 ) discontinue treatment ( see Appendix 6 list medication ) . 6 . Patients nephrotic range proteinuria ( protein creatinine ratio ≥2.0 mg/mg 200 mg/mmol ( Hogg , 2003 ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Paediatric kidney transplantation</keyword>
	<keyword>Early MMF everolimus conversion</keyword>
	<keyword>Composite efficacy ( biopsy-proven acute rejection , graft loss death )</keyword>
	<keyword>Renal function</keyword>
</DOC>